|
|
Post by yash on Sept 7, 2021 5:41:39 GMT -5
|
|
|
|
Post by Clement on Sept 7, 2021 6:37:27 GMT -5
"United Therapeutics and MannKind are also developing BluHale®, a Bluetooth-connected accessory for the Tyvaso DPI inhaler with a companion mobile application intended to help the patient track information about inhaler use."
It sounds like BluHale development is still ongoing and that uthr and mnkd are not holding up Tyvaso DPI because of BluHale. Good. I hope they beta test and beta test some more before they let BluHale out of the gate. (In my experience as a product manager of high precision electromechanical devices for research labs, the engineers would pronounce a project finished when it really was only ready for beta testing. All sorts of interesting quirks and bugs and user interface issues pop up in beta testing.)
|
|
|
|
Post by goyocafe on Sept 7, 2021 9:13:47 GMT -5
"United Therapeutics and MannKind are also developing BluHale®, a Bluetooth-connected accessory for the Tyvaso DPI inhaler with a companion mobile application intended to help the patient track information about inhaler use." It sounds like BluHale development is still ongoing and that uthr and mnkd are not holding up Tyvaso DPI because of BluHale. Good. I hope they beta test and beta test some more before they let BluHale out of the gate. (In my experience as a product manager of high precision electromechanical devices for research labs, the engineers would pronounce a project finished when it really was only ready for beta testing. All sorts of interesting quirks and bugs and user interface issues pop up in beta testing.) But MC promised, this is the 3rd time… www.tickcounter.com/countdown/2200229/bluehale-deadline |
|
|
|
Post by Clement on Sept 7, 2021 9:32:06 GMT -5
If you send to patients this new BluHale product with bugs and problems, it will be rejected and suffer market damage. This fact supercedes a CEO's promise.
|
|
|
|
Post by harryx1 on Sept 7, 2021 9:58:46 GMT -5
|
|
|
|
Post by celo on Sept 7, 2021 10:56:43 GMT -5
The more weeks the patients are on tyvaso DPI the more they improve. To see gradual continuous improvement in the 6 MWD is amazing.
|
|
|
|
Post by stevil on Sept 7, 2021 12:01:09 GMT -5
The more weeks the patients are on tyvaso DPI the more they improve. To see gradual continuous improvement in the 6 MWD is amazing. Which is the biggest reason this will get FDA approval. It’s an improvement over current therapy. |
|
|
|
Post by phdedieu12 on Sept 7, 2021 13:18:59 GMT -5
Have you heard of the chip shortage??
|
|
|
|
Post by markado on Sept 7, 2021 18:41:54 GMT -5
If you send to patients this new BluHale product with bugs and problems, it will be rejected and suffer market damage. This fact supercedes a CEO's promise. The device likely needs to be calibrated for each Technosphere API. Extra care. Extra steps. |
|
|
|
Post by prcgorman2 on Sept 7, 2021 19:57:55 GMT -5
If you send to patients this new BluHale product with bugs and problems, it will be rejected and suffer market damage. This fact supercedes a CEO's promise. The device likely needs to be calibrated for each Technosphere API. Extra care. Extra steps. Not following. Where did the story on the BREEZE study say anything about BluHale? |
|
|
|
Post by longliner on Sept 7, 2021 20:35:35 GMT -5
The device likely needs to be calibrated for each Technosphere API. Extra care. Extra steps. Not following. Where did the story on the BREEZE study say anything about BluHale? United Therapeutics and MannKind are also developing BluHale®, a Bluetooth-connected accessory for the Tyvaso DPI inhaler with a companion mobile application intended to help the patient track information about inhaler use. It was referenced in the link yash provided, prc. |
|
|
|
Post by prcgorman2 on Sept 7, 2021 21:01:53 GMT -5
Guess I need to read more carefully. I looked but didn’t see it. Thanks longliner (and yash, et al).
I think this application may be the first commercial offering of BluHale. I think Dr. Mann would like that. He was a device guy at heart.
|
|
|
|
Post by Thundersnow on Sept 7, 2021 21:34:04 GMT -5
Guess I need to read more carefully. I looked but didn’t see it. Thanks longliner (and yash, et al). I think this application may be the first commercial offering of BluHale. I think Dr. Mann would like that. He was a device guy at heart. To be accurate I don't think BLUHALE was part of the BREEZE Trial. |
|
|
|
Post by anderson on Sept 8, 2021 7:47:08 GMT -5
Have you heard of the chip shortage?? Yeah MC mentioned that in one of the webcasts. The average lead time is now over 20 weeks. |
|
|
|
Post by longliner on Sept 8, 2021 14:58:25 GMT -5
UTHR is rising into the close nicely. Let's hope it's something substantive (and for us as well).
|
|
